Prognostic Implications of Degenerative Mitral Regurgitation on Eligibility for TAVI

Introduction
Degenerative mitral regurgitation (DMR), characterized by the structural deterioration of the mitral valve apparatus, is a common valvular heart disease in elderly populations. Transcatheter aortic valve implantation (TAVI), a minimally invasive procedure for aortic stenosis (AS), is increasingly considered for patients with multiple comorbidities, including DMR. Understanding the prognostic implications of DMR on TAVI eligibility is crucial for optimizing outcomes in this high-risk group.

https://cvia-journal.org/category/news-and-events/page/2/

---

Overview of Degenerative Mitral Regurgitation (DMR)

1. Pathophysiology:
   
   
   
   • Caused by degeneration of mitral valve leaflets and chordae tendineae.
   
   
   • Leads to backward flow of blood into the left atrium during systole.
   
   
   
   


2. Clinical Features:
   
   
   
   • Symptoms include fatigue, dyspnea, and atrial fibrillation (in severe cases).
   
   
   • Severe DMR can cause left atrial dilation, pulmonary hypertension, and heart failure.
   
   
   
   

---

Intersection of DMR and Aortic Stenosis in TAVI Candidates

1. Pathophysiological Interplay:
   
   
   
   • Aortic stenosis (AS) increases left ventricular afterload, exacerbating mitral regurgitation.
   
   
   • Addressing AS via TAVI may improve hemodynamics and reduce the severity of DMR in some cases.
   
   
   
   


2. Prognostic Concerns:
   
   
   
   • Severe DMR often complicates decision-making for TAVI.
   
   
   • Patients with severe DMR may have a higher risk of poor post-procedural outcomes, including heart failure and mortality.
   
   
   
   

---

Impact of DMR on TAVI Eligibility

1. Assessment of DMR Severity:
   
   
   
   • Echocardiography is the gold standard for evaluating mitral valve function and severity of regurgitation.
   
   
   • Cardiac magnetic resonance imaging (MRI) may provide additional details in complex cases.
   
   
   
   


2. Exclusion Criteria for TAVI:
   
   
   
   • Patients with severe symptomatic DMR not amenable to repair or replacement may not benefit from TAVI alone.
   
   
   • Presence of severe pulmonary hypertension or right heart failure due to DMR may contraindicate TAVI.
   
   
   
   


3. Integrated Assessment:
   
   
   
   • Multidisciplinary heart team evaluation, including cardiologists, cardiac surgeons, and imaging specialists, is essential for eligibility determination.
   
   
   
   

---

Prognostic Implications

1. Outcomes After TAVI in DMR Patients:
   
   
   
   • Improved Hemodynamics: TAVI may reduce left ventricular afterload, indirectly alleviating functional mitral regurgitation.
   
   
   • Persistent DMR: Structural (degenerative) mitral regurgitation is less likely to improve after TAVI, requiring separate intervention.
   
   
   
   


2. Mortality and Morbidity:
   
   
   
   • Severe pre-existing DMR is associated with higher mortality and rehospitalization rates post-TAVI.
   
   
   • Increased risk of heart failure exacerbation in patients with untreated severe DMR.
   
   
   
   


3. Predictive Factors for Poor Outcomes:
   
   
   
   • Reduced left ventricular ejection fraction (LVEF).
   
   
   • Severe pulmonary hypertension or right ventricular dysfunction.
   
   
   • Frailty and high comorbidity burden.
   
   
   
   

---

Strategies for Optimizing Outcomes

1. Simultaneous Valve Interventions:
   
   
   
   • For select patients, combining TAVI with transcatheter mitral valve repair or replacement may be beneficial.
   
   
   
   


2. Advanced Imaging:
   
   
   
   • Use of three-dimensional echocardiography and computed tomography for precise anatomical evaluation of both valves.
   
   
   
   


3. Pharmacological Management:
   
   
   
   • Optimizing heart failure medications, such as beta-blockers, ACE inhibitors, and diuretics, prior to and after TAVI.
   
   
   
   


4. Post-TAVI Follow-Up:
   
   
   
   • Regular imaging to monitor mitral valve function and detect progression of regurgitation.
   
   
   
   

---

Future Directions

1. Clinical Trials:
   
   
   
   • Studies assessing the outcomes of combined transcatheter interventions for AS and DMR.
   
   
   
   


2. Technology Advancements:
   
   
   
   • Development of devices designed for simultaneous repair or replacement of multiple valves.
   
   
   
   


3. Patient Selection:
   
   
   
   • Improved risk stratification tools for better decision-making in TAVI candidates with DMR.
   
   
   
   

---

Conclusion

Degenerative mitral regurgitation significantly impacts the prognosis and eligibility for TAVI in patients with aortic stenosis. A tailored, multidisciplinary approach is essential to optimize outcomes. Future innovations in transcatheter therapies and clinical research may expand treatment options for this challenging population.